A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumours With an Expansion Cohort in Metastatic Colorectal Cancer
This phase I/Ib trial studies the side effects and best dose of selumetinib when given
together with cyclosporine in treating patients with solid tumours or colorectal cancer that
have spread to other places in the body and cannot be cured or controlled with treatment.
Selumetinib may stop the growth of tumour cells by blocking some of the enzymes needed for
cell growth. Biological therapies, such as cyclosporine, use substances made from living
organisms that may stimulate or suppress the immune system in different ways and stop tumour
cells from growing. Giving selumetinib and cyclosporine may be a better treatment for solid
tumours or colorectal cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society